Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
SYDNEY--(BUSINESS WIRE)--As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class.
LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain.
According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities.
Highlights from the report include:
A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH.
Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation.
North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific.
A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030.
The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023.
With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution.
Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success.
Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here.
For further information, please visit novotech-cro.com.
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
28 minutes ago
- Business Wire
Generation Mining Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Generation Mining Limited (TSX:GENM, OTCQB: GENMF) (the 'Company ') announces the voting results from its annual meeting of shareholders (the ' Meeting ') held earlier today. The five (5) candidates nominated for election to the Company's board of directors and listed in the Company's Management Information Circular dated May 15, 2025, were each elected by a majority of the votes cast by shareholders present in person or represented by proxy at the Meeting. Each director elected will continue to hold office until the next annual meeting of Shareholders, or until a successor is elected or appointed. The voting results were as follows: Shareholders of the Company also voted in favour of a resolution to re-appoint RSM Canada LLP as the auditor of the Company until the next annual meeting of Shareholders and the board of directors were authorized to fix the remuneration of the auditor. The full report of voting results from the Meeting is available under the Company's issuer profile on SEDAR+ at
Business Wire
2 hours ago
- Business Wire
Armanino Foods Reports Quarterly Dividend and Announces Shareholder Meeting Date
PLEASANTON, Calif.--(BUSINESS WIRE)-- Armanino Foods of Distinction, Inc. (OTCQX: AMNF) today announced that its Board of Directors has declared a quarterly cash dividend of $0.04 per share on its common stock. The dividend will be payable on or about July 27, 2025 to shareholders of record on July 7, 2025. This is the Company's 100 th consecutive quarterly dividend. The Company has also paid out eleven special dividends. Additionally, the Company announced that it will hold an Annual Meeting of Shareholders on September 24, 2025, at 9:00 a.m. Pacific Time. The Annual Meeting will take place near the Company's headquarters in Pleasanton, CA. Full details regarding the Annual Meeting will be included in the Company's proxy materials, set to be delivered to shareholders in August 2025. Armanino Foods of Distinction, Inc. is an international food company that manufactures and markets frozen Italian specialty food items to the foodservice, retail, and industrial markets. In addition to a classic Basil Pesto, Armanino offers other flavors and sauces including Cilantro, Dried Tomato & Garlic, Roasted Red Bell Pepper, Southwest Chipotle, Artichoke, Roasted Garlic, Light Basil Pesto, Chimichurri, Harissa, Bolognese, and Alfredo. Armanino's organic line includes classic Basil Pesto. Finally, Armanino Foods also offers cheese shakers, frozen pastas, and meatballs. Cautionary Statements Regarding Forward-Looking Information Statements in this news release regarding our expectations and beliefs about our future financial performance and trends in our markets are 'forward-looking statements' as defined in the Private Securities Litigations Reform Act of 1995. Forward-looking statements often include the words 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' 'project,' or words of similar meaning, or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' or 'may.' The forward-looking statements in this news release regarding our future financial performance are based on current information and because our business is subject to several risks and uncertainties, actual operating results in the future may differ significantly from the future financial performance expected at the current time. Those risks and uncertainties may include, among others: economic factors affecting consumer confidence and discretionary spending and reducing the consumption of food prepared away from home; the extent and duration of the negative impact of the COVID-19 pandemic and its consequences on the Company; cost inflation/deflation and commodity volatility; competition; reliance on third party suppliers and interruption of product supply or increases in product costs; changes in the Company's relationships with customers and group purchasing organizations; the Company's ability to increase or maintain the highest margin portions of the Company's business; achievement of expected benefits from cost savings initiatives; increases in fuel costs; changes in consumer eating habits; cost and pricing structures and other governmental regulation, including actions taken by national, state and local governments to contain and/or respond to the COVID-19 pandemic and its consequences; product recalls and product liability claims; and our reputation in the industry. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on information and estimates available to the Company at this time. We undertake no obligation to update or revise any forward-looking statements, except as may be required by law. The best source of information on the company is the OTC Markets website (
Business Wire
2 hours ago
- Business Wire
Abnormal AI Launches in Japan to Deliver AI-Native Email Security to Local Enterprises
TOKYO--(BUSINESS WIRE)-- Abnormal AI, the leader in AI-native human behavior security, today announced the launch of its operations in Japan. This expansion strengthens the company's operations in Asia-Pacific and reinforces its commitment to protecting enterprises worldwide from advanced email threats using behavioral AI. 'Japan is a cornerstone of our international growth strategy,' said Evan Reiser, Co-Founder and CEO of Abnormal AI. 'As the third-largest economy and one of the most technologically advanced markets in the world, Japan presents a tremendous opportunity for Abnormal. We are committed to investing in the region to help Japanese enterprises redefine email security in the era of AI.' The launch comes amid a sharp rise in socially-engineered email attacks targeting Japanese businesses. Traditional security tools often fall short against these sophisticated threats, which is where Abnormal AI's platform stands apart. Built on a cloud-native architecture and powered by behavioral AI, Abnormal's AI-native platform precisely stops the full spectrum of advanced email attacks—including phishing, business email compromise, vendor fraud, and emerging threats—by detecting anomalies among known normal behavior. 'Abnormal leverages AI-native technology to proactively detect and stop sophisticated cyber threats powered by malicious AI—threats that frequently evade traditional defenses,' said Kei Mitsuyama, Country Manager for Abnormal AI Japan. 'Our advanced AI-driven approach not only increases threat detection accuracy, but also simplifies operations, reducing the burden on already-stretched security teams.' The launch builds on Abnormal AI's momentum across the broader Asia-Pacific region, where the company is rapidly expanding its customer base and local teams to meet surging demand. 'We've seen remarkable growth across the region as organizations increasingly recognize the need for modern, AI-powered security solutions,' said Tim Bentley, Vice President of Asia-Pacific at Abnormal AI. 'Japan is a strategic market for us, and we're excited to partner with leading enterprises here to deliver better protection with less complexity.' Abnormal AI will be exhibiting at the Gartner Security and Risk Management Summit in Tokyo from July 23–25, where it will showcase its behavioral AI platform and discuss best practices for securing the modern workplace against today's most advanced threats. For more information about Abnormal AI and its email security solutions, please visit About Abnormal AI Abnormal AI is the leading AI-native human behaviour security platform, leveraging machine learning to stop sophisticated inbound attacks and detect compromised accounts across email and connected applications. The anomaly detection engine leverages identity and context to understand human behaviour and analyse the risk of every cloud email event—detecting and stopping sophisticated, socially-engineered attacks that target the human vulnerability. You can deploy Abnormal in minutes with an API integration for Microsoft 365 or Google Workspace and experience the full value of the platform instantly. Additional protection is available for Slack, Workday, ServiceNow, Zoom, and multiple other cloud applications. Abnormal is currently trusted by more than 3,200 organisations, including over 20% of the Fortune 500, as it continues to redefine how cybersecurity works in the age of AI. Learn more at
